| Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients EQ Wu, S Johnson, N Beaulieu, M Arana, V Bollu, A Guo, J Coombs, ... Current medical research and opinion 26 (1), 61-69, 2010 | 168 | 2010 |
| Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia EQ Wu, A Guerin, AP Yu, VK Bollu, A Guo, JD Griffin Current medical research and opinion 26 (12), 2861-2869, 2010 | 81 | 2010 |
| Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials JE Signorovitch, EQ Wu, KA Betts, K Parikh, E Kantor, A Guo, VK Bollu, ... Current medical research and opinion 27 (6), 1263-1271, 2011 | 78 | 2011 |
| Epidemiology, survival, and costs of localized gastrointestinal stromal tumors JL Rubin, M Sanon, DCA Taylor, J Coombs, V Bollu, L Sirulnik International journal of general medicine, 121-130, 2011 | 72 | 2011 |
| Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia. M StCharles, VK Bollu, E Hornyak, J Coombs, CM Blanchette, ... Blood 114 (22), 2209, 2009 | 61 | 2009 |
| Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD V Bollu, FR Ernst, J Karafilidis, K Rajagopalan, SB Robinson, SS Braman International journal of chronic obstructive pulmonary disease, 631-639, 2013 | 38 | 2013 |
| Healthcare utilization and costs in patients beginning pharmacotherapy for generalized anxiety disorder: a retrospective cohort study A Berger, J Edelsberg, V Bollu, JMJ Alvir, A Dugar, AV Joshi, G Oster BMC psychiatry 11, 1-9, 2011 | 25 | 2011 |
| Cost-effectiveness analysis of tisagenlecleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma in the United States CZ Qi, V Bollu, H Yang, A Dalal, S Zhang, J Zhang Clinical Therapeutics 43 (8), 1300-1319. e8, 2021 | 22 | 2021 |
| Clinical and economic burden of breakthrough seizures V Divino, AA Petrilla, V Bollu, F Velez, A Ettinger, C Makin Epilepsy & Behavior 51, 40-47, 2015 | 21 | 2015 |
| Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms V Bollu, AG Bushmakin, JC Cappelleri, CC Chen, D Feltner, HU Wittchen The European journal of psychiatry 24 (1), 18-27, 2010 | 20 | 2010 |
| Treatment patterns for patients hospitalized with chronic obstructive pulmonary disease AN Amin, V Bollu, MD Stensland, L Netzer, V Ganapathy The Bulletin of the American Society of Hospital Pharmacists 75 (6), 359-366, 2018 | 14 | 2018 |
| A retrospective cohort study of treatment outcomes of adult patients with relapsed or refractory follicular lymphoma (ReCORD-FL) G Salles, SJ Schuster, L Fischer, J Kuruvilla, PEM Patten, B Von Tresckow, ... Hemasphere 6 (7), e745, 2022 | 12 | 2022 |
| Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized β2-Agonists V Bollu, A Guérin, G Gauthier, R Hiscock, EQ Wu Drugs-Real World Outcomes 4, 33-41, 2017 | 11 | 2017 |
| Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: an analysis … RT Maziarz, H Yang, Q Liu, T Wang, J Zhao, S Lim, S Lee, A Dalal, ... Leukemia & Lymphoma 63 (9), 2052-2062, 2022 | 10 | 2022 |
| Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed/refractory large B-cell lymphomas: an indirect treatment comparison SJ Schuster, J Zhang, H Yang, A Agarwal, W Tang, M Martinez-Prieto, ... Leukemia & lymphoma 63 (4), 845-854, 2022 | 10 | 2022 |
| Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors JL Rubin, DCA Taylor, M Sanon, JH Coombs, VK Bollu Journal of Managed Care Pharmacy 16 (7), 482-491, 2010 | 10 | 2010 |
| Multi-stakeholder qualitative interviews to inform measurement of patient reported outcomes after CAR-T IM Akinola, R Cusatis, MC Pasquini, BE Shaw, V Bollu, A Dalal, ... Transplantation and cellular therapy 29 (4), 254. e1-254. e9, 2023 | 8 | 2023 |
| Assessment of healthcare resource utilization and costs in patients with relapsed or refractory follicular lymphoma undergoing CAR-T cell therapy with tisagenlecleucel: results … NH Fowler, M Dickinson, M Ghosh, A Chen, C Andreadis, R Tiwari, ... Blood 138, 3533, 2021 | 8 | 2021 |
| Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy V Bollu, F Ejzykowicz, K Rajagopalan, J Karafilidis, JW Hay Journal of Medical Economics 16 (8), 1082-1088, 2013 | 8 | 2013 |
| Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-acting β2-agonists YJ Chen, C Makin, VK Bollu, M Navaie, BR Celli Journal of Medical Economics 19 (1), 11-20, 2016 | 7 | 2016 |
